|
|
|
|
| LEADER |
05640nam a2200673 4500 |
| 001 |
ocn900942915 |
| 003 |
OCoLC |
| 005 |
20180501122024.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
150129s2015 ne af ob 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d UIU
|d OPELS
|d OCLCF
|d EBLCP
|d IDEBK
|d CDX
|d DEBSZ
|d YDXCP
|d OCLCQ
|d DEBBG
|d MEU
|d GrThAP
|
| 019 |
|
|
|a 902956991
|
| 020 |
|
|
|a 9780128013618
|q (electronic bk.)
|
| 020 |
|
|
|a 0128013613
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128012512
|
| 020 |
|
|
|a 012801251X
|
| 035 |
|
|
|a (OCoLC)900942915
|z (OCoLC)902956991
|
| 050 |
|
4 |
|a RC267
|b .A383 2015eb
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99406
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a ABC Transporters and Cancer /
|c edited by John D. Schuetz, Toshihisa Ishikawa.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier Ltd.,
|c 2015.
|
| 300 |
|
|
|a 1 online resource (280 pages, 10 unnumbered pages of plates) :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in cancer research ;
|v v. 125
|
| 546 |
|
|
|a Text in English.
|
| 504 |
|
|
|a Includes bibliographical references at the end of each chapters and index.
|
| 520 |
|
|
|a ABC Transporters and Cancer provides invaluable information on the exciting and fast-moving field of cancer research. Here, outstanding and original reviews are presented on a variety of topics. This volume covers ABC transporters and cancer, and is suitable for researchers and students alike.
|
| 505 |
0 |
|
|a Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability.
|
| 505 |
8 |
|
|a 2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates.
|
| 505 |
8 |
|
|a 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins.
|
| 505 |
8 |
|
|a 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s ... 3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References.
|
| 505 |
8 |
|
|a Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th ... ; 5.1. P-glycoprotein.
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Drug resistance in cancer cells.
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy.
|2 fast
|0 (OCoLC)fst00845327
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 650 |
|
7 |
|a Drug resistance in cancer cells.
|2 fast
|0 (OCoLC)fst00898703
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Schuetz, John D.,
|e editor.
|
| 700 |
1 |
|
|a Ishikawa, Toshihisa,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Ishikawa, Toshihisa.
|t ABC Transporters and Cancer.
|d Burlington : Elsevier Science, ©2015
|z 9780128012512
|
| 830 |
|
0 |
|a Advances in cancer research ;
|v v. 125.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/0065230X/125
|z Full Text via HEAL-Link
|
